Curanex Pharmaceuticals Inc
CURX
$4.20
-$0.84-16.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 2.59M | 2.26M | 2.31M | 677.50K | -- |
| Gross Profit | -2.59M | -2.26M | -2.31M | -677.50K | -- |
| SG&A Expenses | 731.80K | 927.20K | 786.30K | 273.90K | 57.70K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.33M | 3.18M | 3.09M | 951.30K | 57.70K |
| Operating Income | -3.33M | -3.18M | -3.09M | -951.30K | -57.70K |
| Income Before Tax | -3.29M | -3.15M | -3.07M | -954.10K | -60.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.29M | -3.15M | -3.07M | -954.10K | -60.30K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.29M | -3.15M | -3.07M | -954.10K | -60.30K |
| EBIT | -3.33M | -3.18M | -3.09M | -951.30K | -57.70K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.32 | -2.22 | -2.17 | -0.75 | -0.05 |
| Normalized Basic EPS | -1.45 | -1.39 | -1.35 | -0.47 | -0.03 |
| EPS Diluted | -2.32 | -2.22 | -2.17 | -0.75 | -0.05 |
| Normalized Diluted EPS | -1.45 | -1.39 | -1.35 | -0.47 | -0.03 |
| Average Basic Shares Outstanding | 1.42M | 1.42M | 1.42M | 1.28M | 1.20M |
| Average Diluted Shares Outstanding | 1.42M | 1.42M | 1.42M | 1.28M | 1.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |